September 26, 2017 / 11:28 AM / 23 days ago

BRIEF-BioTime announces positive data from Renevia pivotal trial

Sept 26 (Reuters) - BioTime Inc

* BioTime announces positive secondary and additional positive long-term data from the Renevia® pivotal trial

* BioTime Inc - ‍filing for Renevia CE mark by end of 2017​

* BioTime Inc - ‍preliminary data for five patients indicates an average retention of 64% of transplanted volume at 18 months​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below